Company intelligence / Profile preview
EirGenix
New Taipei City, Taiwaneirgenix.com ↗
- Ownership
- Private
- Employees
- ~1000
- Development stage
- Other
01
Overview
EirGenix has successfully completed Phase III clinical trials for its trastuzumab biosimilar EG12014, demonstrating bioequivalence to Roche’s Herceptin®. The company has submitted a BLA to the US FDA and is in the regulatory filing stage. Other pipeline programs are at earlier stages ranging from preclinical to Phase 1.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodies (mAbs)Bi-specific mAbsRecombinant proteinsAntibody-drug conjugates (ADCs)Fusion proteinsRNA-based therapeuticsViral vectors
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Sandoz – global licensing collaboration for Trastuzumab biosimilar (EG12014)Bolt Biotherapeutics – customer relationship
Beyond the preview
Go deeper on EirGenix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EirGenix.